副甲状腺機能低下症の世界市場レポート2025年

副甲状腺機能低下症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.3％で14億2,000万米ドルに成長します。予測期間中の成長は、遺伝子組換え副甲状腺ホルモン療法の採用増加、副甲状腺機能低下症調査への投資増加、ヘルスケアインフラの拡大、内分泌障害に脆弱な高齢者人口の増加、認知度向上と早期診断への取り組みに起因しています。この期間の主な動向としては、副甲状腺ホルモン療法の発展、副甲状腺機能低下症の診断技術の向上、徐放性カルシウムサプリメントの開発、低侵襲甲状腺手術の革新、患者モニタリング技術の進歩などが挙げられます。

甲状腺がんの罹患率の上昇が、今後数年間の副甲状腺機能低下症市場の成長を牽引すると予想されます。甲状腺がんは、甲状腺の異常な細胞増殖を特徴とするがんの一種であり、しばしば頸部にしこりをもたらします。甲状腺がん患者の増加は、無症状の小さな甲状腺結節をより早く、より頻繁に発見できるようになった画像診断技術の進歩に起因しています。甲状腺がんは、意図せず副甲状腺を損傷する可能性のある甲状腺手術の数を増やすことによって、副甲状腺機能低下症に寄与しています。この損傷はカルシウムの不均衡と慢性的なホルモン欠乏症につながり、長期的な疾病管理ソリューションの需要を押し上げます。例えば、2024年5月、米国の非営利団体である米国がん協会は、甲状腺がんの新規症例数が2023年の4万3,720人から2025年には4万4,020人に達すると予測されると報告しました。このように、甲状腺がん症例の増加が副甲状腺機能低下症市場の拡大を後押ししています。

副甲状腺機能低下症市場の主要企業は、治療効果を高め、患者の予後を改善するために、TransCon技術に基づく製品など、技術的に先進的な製品の開発に注力しています。TransCon（Transient Conjugation）技術は、ドラッグデリバリーを最適化するために設計された独自のプラットフォームです。例えば、2024年1月、デンマークを拠点とするバイオ医薬品会社Ascendis Pharma A/Sは、TransCon技術を利用した2番目の製品であるYORVIPATH（palopegteriparatide）を、成人の慢性副甲状腺機能低下症治療薬としてドイツとオーストリアで発売しました。YORVIPATHは1日1回投与の副甲状腺ホルモン（PTH 1-34）のプロドラッグで、24時間にわたって生理的なPTHレベルを維持するように設計されており、慢性副甲状腺機能低下症の根底にあるホルモン欠乏症に効果的に対処します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の副甲状腺機能低下症：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の副甲状腺機能低下症市場：成長率分析
• 世界の副甲状腺機能低下症市場の実績：規模と成長, 2019-2024
• 世界の副甲状腺機能低下症市場の予測：規模と成長, 2024-2029, 2034F
• 世界の副甲状腺機能低下症：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の副甲状腺機能低下症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン補充療法
• 補助療法
• 世界の副甲状腺機能低下症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン補充療法
• カルシウムとビタミンDのサプリメント
• 新興治療法
• 世界の副甲状腺機能低下症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の副甲状腺機能低下症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の副甲状腺機能低下症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ケア設定
• 世界の副甲状腺機能低下症市場ホルモン補充療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組換え副甲状腺ホルモン
• 副甲状腺ホルモン類似体
• カルシウム刺激薬
• カルシウムとビタミンDのサプリメント
• 世界の副甲状腺機能低下症市場補助療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• マグネシウムサプリメント
• リン酸結合剤
• その他の支持療法

第7章 地域別・国別分析

• 世界の副甲状腺機能低下症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の副甲状腺機能低下症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 副甲状腺機能低下症市場：競合情勢
• 副甲状腺機能低下症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Eagle Pharmaceuticals Inc.
• BridgeBio Pharma Inc.
• Ascendis Pharma A/S
• Extend Biosciences Inc.
• Entera Bio Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 副甲状腺機能低下症市場2029：新たな機会を提供する国
• 副甲状腺機能低下症市場2029：新たな機会を提供するセグメント
• 副甲状腺機能低下症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH) by the parathyroid glands, resulting in low calcium and high phosphorus levels in the blood. The main role of parathyroid hormone (PTH) is to regulate and maintain stable calcium and phosphorus levels, which are vital for nerve, muscle, and bone function. Hypoparathyroidism may occur due to surgical removal or damage to the parathyroid glands, autoimmune diseases, genetic disorders, or, in rare cases, unknown causes.

The primary treatments for hypoparathyroidism include hormone replacement therapy and adjunctive therapies. Hormone replacement therapy (HRT) involves administering hormones to replace or supplement those that the body no longer produces adequately. Treatment options include hormone replacement therapy, calcium and vitamin D supplements, and emerging therapies. These treatments are administered through oral or parenteral routes and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, serving various end users such as hospitals, specialty clinics, and homecare settings.

The hypoparathyroidism market research report is one of a series of new reports from The Business Research Company that provides hypoparathyroidism market statistics, including hypoparathyroidism industry global market size, regional shares, competitors with hypoparathyroidism market share, hypoparathyroidism market segments, market trends and opportunities, and any further data you may need to thrive in the hypoparathyroidism industry. This hypoparathyroidism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypoparathyroidism market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising number of thyroid surgeries, increased awareness of hypoparathyroidism, a rise in postoperative complications, growing demand for calcium and vitamin D supplements, and heightened focus on managing endocrine disorders.

The hypoparathyroidism market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth during the forecast period can be attributed to the increasing adoption of recombinant parathyroid hormone therapies, rising investment in hypoparathyroidism research, expansion of healthcare infrastructure, a growing geriatric population vulnerable to endocrine disorders, and enhanced awareness and early diagnosis efforts. Key trends in this period include advancements in parathyroid hormone therapies, improved diagnostic techniques for hypoparathyroidism, development of sustained-release calcium supplements, innovations in minimally invasive thyroid surgery, and progress in patient monitoring technologies.

The rising incidence of thyroid cancer is expected to drive the growth of the hypoparathyroidism market in the coming years. Thyroid cancer is a type of cancer characterized by abnormal cell growth in the thyroid gland, often resulting in a lump in the neck. The increase in thyroid cancer cases is attributed to advancements in diagnostic imaging technologies, which allow for earlier and more frequent detection of small, asymptomatic thyroid nodules. Thyroid cancer contributes to hypoparathyroidism by increasing the number of thyroid surgeries, which can unintentionally damage the parathyroid glands. This damage leads to calcium imbalances and chronic hormone deficiency, boosting the demand for long-term disease management solutions. For example, in May 2024, the American Cancer Society, a US-based non-profit organization, reported that new thyroid cancer cases were projected to reach 44,020 in 2025, up from 43,720 in 2023. Thus, the growing number of thyroid cancer cases is fueling the expansion of the hypoparathyroidism market.

Leading companies in the hypoparathyroidism market are concentrating on developing technologically advanced products, such as those based on TransCon technology, to enhance treatment effectiveness and improve patient outcomes. TransCon (Transient Conjugation) technology is a proprietary platform designed to optimize drug delivery. For example, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide), its second product utilizing TransCon technology, in Germany and Austria for treating adults with chronic hypoparathyroidism. YORVIPATH is a once-daily prodrug of parathyroid hormone (PTH 1-34) engineered to maintain physiological PTH levels over 24 hours, effectively addressing the hormone deficiency underlying chronic hypoparathyroidism.

In July 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Amolyt Pharma SAS for an undisclosed sum. Through this acquisition, AstraZeneca intends to bolster its rare disease portfolio, especially within endocrine disorders, by leveraging Amolyt Pharma's innovative pipeline and clinical-stage therapies. Amolyt Pharma SAS, based in France, is a biotechnology firm developing eneboparatide, a long-acting parathyroid hormone analog for hypoparathyroidism treatment.

Major players in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoparathyroidism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypoparathyroidism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypoparathyroidism market consists of revenues earned by entities by providing services such as diagnostic testing, patient monitoring, telemedicine consultations, and specialized care for chronic disease management and education. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoparathyroidism market also includes sales of phosphate binders, and medical devices or diagnostic kits used for monitoring calcium, phosphorus, and parathyroid Hormone levels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypoparathyroidism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypoparathyroidism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypoparathyroidism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypoparathyroidism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Hormone Replacement Therapy; Adjunctive Therapies
• 2) By Type: Hormone Replacement Therapy; Calcium And Vitamin D Supplements; Emerging Therapies
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By End User: Hospitals; Specialty Clinics; Homecare Settings
• Subsegments:
• 1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone; Parathyroid Hormone Analogues; Calcimimetics; Calcium And Vitamin D Supplements
• 2) By Adjunctive Therapies: Magnesium Supplements; Phosphate Binders; Other Supportive Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypoparathyroidism Market Characteristics

3. Hypoparathyroidism Market Trends And Strategies

4. Hypoparathyroidism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hypoparathyroidism Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypoparathyroidism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypoparathyroidism Market Growth Rate Analysis
• 5.4. Global Hypoparathyroidism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypoparathyroidism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypoparathyroidism Total Addressable Market (TAM)

6. Hypoparathyroidism Market Segmentation

• 6.1. Global Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Replacement Therapy
• Adjunctive Therapies
• 6.2. Global Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Replacement Therapy
• Calcium And Vitamin D Supplements
• Emerging Therapies
• 6.3. Global Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Hypoparathyroidism Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Hypoparathyroidism Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• 6.6. Global Hypoparathyroidism Market, Sub-Segmentation Of Hormone Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Parathyroid Hormone
• Parathyroid Hormone Analogues
• Calcimimetics
• Calcium And Vitamin D Supplements
• 6.7. Global Hypoparathyroidism Market, Sub-Segmentation Of Adjunctive Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Magnesium Supplements
• Phosphate Binders
• Other Supportive Therapies

7. Hypoparathyroidism Market Regional And Country Analysis

• 7.1. Global Hypoparathyroidism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypoparathyroidism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypoparathyroidism Market

• 8.1. Asia-Pacific Hypoparathyroidism Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypoparathyroidism Market

• 9.1. China Hypoparathyroidism Market Overview
• 9.2. China Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypoparathyroidism Market

• 10.1. India Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypoparathyroidism Market

• 11.1. Japan Hypoparathyroidism Market Overview
• 11.2. Japan Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypoparathyroidism Market

• 12.1. Australia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypoparathyroidism Market

• 13.1. Indonesia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypoparathyroidism Market

• 14.1. South Korea Hypoparathyroidism Market Overview
• 14.2. South Korea Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypoparathyroidism Market

• 15.1. Western Europe Hypoparathyroidism Market Overview
• 15.2. Western Europe Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypoparathyroidism Market

• 16.1. UK Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypoparathyroidism Market

• 17.1. Germany Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypoparathyroidism Market

• 18.1. France Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypoparathyroidism Market

• 19.1. Italy Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypoparathyroidism Market

• 20.1. Spain Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypoparathyroidism Market

• 21.1. Eastern Europe Hypoparathyroidism Market Overview
• 21.2. Eastern Europe Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypoparathyroidism Market

• 22.1. Russia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypoparathyroidism Market

• 23.1. North America Hypoparathyroidism Market Overview
• 23.2. North America Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypoparathyroidism Market

• 24.1. USA Hypoparathyroidism Market Overview
• 24.2. USA Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypoparathyroidism Market

• 25.1. Canada Hypoparathyroidism Market Overview
• 25.2. Canada Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypoparathyroidism Market

• 26.1. South America Hypoparathyroidism Market Overview
• 26.2. South America Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypoparathyroidism Market

• 27.1. Brazil Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypoparathyroidism Market

• 28.1. Middle East Hypoparathyroidism Market Overview
• 28.2. Middle East Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypoparathyroidism Market

• 29.1. Africa Hypoparathyroidism Market Overview
• 29.2. Africa Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypoparathyroidism Market Competitive Landscape And Company Profiles

• 30.1. Hypoparathyroidism Market Competitive Landscape
• 30.2. Hypoparathyroidism Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Hypoparathyroidism Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Cipla Limited
• 31.9. Lupin Limited
• 31.10. Torrent Pharmaceuticals Ltd.
• 31.11. Eagle Pharmaceuticals Inc.
• 31.12. BridgeBio Pharma Inc.
• 31.13. Ascendis Pharma A/S
• 31.14. Extend Biosciences Inc.
• 31.15. Entera Bio Ltd.

32. Global Hypoparathyroidism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypoparathyroidism Market

34. Recent Developments In The Hypoparathyroidism Market

35. Hypoparathyroidism Market High Potential Countries, Segments and Strategies

• 35.1 Hypoparathyroidism Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypoparathyroidism Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypoparathyroidism Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer